$CAPR
CAPRICOR THERAPEUTICS, INC.

2024 Q4 Form 10-Q Financial Statement

#000155837024015730 Filed on November 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $2.262M
YoY Change -63.44%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.464M
YoY Change 14.69%
% of Gross Profit
Research & Development $11.80M
YoY Change 18.0%
% of Gross Profit
Depreciation & Amortization $361.2K
YoY Change 30.63%
% of Gross Profit
Operating Expenses $15.27M
YoY Change 17.02%
Operating Profit -$13.01M
YoY Change 89.52%
Interest Expense $453.2K
YoY Change -5.59%
% of Operating Profit
Other Income/Expense, Net $453.2K
YoY Change -4.4%
Pretax Income -$12.56M
YoY Change 96.51%
Income Tax
% Of Pretax Income
Net Earnings -$12.56M
YoY Change 96.49%
Net Earnings / Revenue -555.2%
Basic Earnings Per Share -$0.38
Diluted Earnings Per Share -$0.38
COMMON SHARES
Basic Shares Outstanding 45.47M 32.54M
Diluted Shares Outstanding 33.09M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $85.03M
YoY Change 198.14%
Cash & Equivalents $68.38M
Short-Term Investments $16.65M
Other Short-Term Assets $385.1K
YoY Change -16.29%
Inventory
Prepaid Expenses
Receivables $409.7K
Other Receivables $0.00
Total Short-Term Assets $85.82M
YoY Change 190.66%
LONG-TERM ASSETS
Property, Plant & Equipment $5.315M
YoY Change 3.42%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $319.3K
YoY Change 18.24%
Total Long-Term Assets $7.128M
YoY Change -6.51%
TOTAL ASSETS
Total Short-Term Assets $85.82M
Total Long-Term Assets $7.128M
Total Assets $92.95M
YoY Change 150.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.531M
YoY Change -3.81%
Accrued Expenses $813.6K
YoY Change 11.46%
Deferred Revenue $13.13M
YoY Change -48.32%
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $20.48M
YoY Change -37.81%
LONG-TERM LIABILITIES
Long-Term Debt $3.376M
YoY Change -0.11%
Other Long-Term Liabilities $834.9K
YoY Change -68.38%
Total Long-Term Liabilities $4.211M
YoY Change -29.97%
TOTAL LIABILITIES
Total Short-Term Liabilities $20.48M
Total Long-Term Liabilities $4.211M
Total Liabilities $24.69M
YoY Change -36.6%
SHAREHOLDERS EQUITY
Retained Earnings -$192.7M
YoY Change 21.5%
Common Stock $260.9M
YoY Change 66.48%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $68.26M
YoY Change
Total Liabilities & Shareholders Equity $92.95M
YoY Change 150.19%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$12.56M
YoY Change 96.49%
Depreciation, Depletion And Amortization $361.2K
YoY Change 30.63%
Cash From Operating Activities -$11.64M
YoY Change 32.45%
INVESTING ACTIVITIES
Capital Expenditures $59.03K
YoY Change -90.63%
Acquisitions
YoY Change
Other Investing Activities $2.064M
YoY Change -75.29%
Cash From Investing Activities $2.005M
YoY Change -74.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 67.33M
YoY Change 30503.12%
NET CHANGE
Cash From Operating Activities -11.64M
Cash From Investing Activities 2.005M
Cash From Financing Activities 67.33M
Net Change In Cash 57.69M
YoY Change -6886.95%
FREE CASH FLOW
Cash From Operating Activities -$11.64M
Capital Expenditures $59.03K
Free Cash Flow -$11.70M
YoY Change 24.22%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001133869
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40332392
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31148320
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31148320
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40332392
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-34058
dei Entity Registrant Name
EntityRegistrantName
CAPRICOR THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
88-0363465
dei Entity Address Address Line1
EntityAddressAddressLine1
10865 Road to the Cure, Suite 150
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
727-1755
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
CAPR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
45469908
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68377402
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14694857
CY2024Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
16651222
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
24792846
CY2024Q3 us-gaap Grants Receivable Current
GrantsReceivableCurrent
409682
CY2023Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
10371993
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
385065
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
995776
CY2024Q3 us-gaap Assets Current
AssetsCurrent
85823371
CY2023Q4 us-gaap Assets Current
AssetsCurrent
50855472
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5315385
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5560641
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1493611
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2050042
CY2024Q3 us-gaap Other Assets
OtherAssets
319246
CY2023Q4 us-gaap Other Assets
OtherAssets
268172
CY2024Q3 us-gaap Assets
Assets
92951613
CY2023Q4 us-gaap Assets
Assets
58734327
CY2024Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6531363
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
6250241
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
813634
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
749112
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
13130509
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
24270465
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
20475506
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
31269818
CY2024Q3 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
3376259
CY2023Q4 us-gaap Other Long Term Debt Noncurrent
OtherLongTermDebtNoncurrent
3376259
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
834889
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1486783
CY2024Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
4211148
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
4863042
CY2024Q3 us-gaap Liabilities
Liabilities
24686654
CY2023Q4 us-gaap Liabilities
Liabilities
36132860
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40332392
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
40332
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
31148
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
260846342
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
181701859
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
96221
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
235813
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-192717936
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-159367353
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
68264959
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
22601467
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
92951613
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
58734327
CY2024Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
2261642
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
6185814
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
11139956
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
13089977
CY2024Q3 us-gaap Revenues
Revenues
2261642
CY2023Q3 us-gaap Revenues
Revenues
6185814
us-gaap Revenues
Revenues
11139956
us-gaap Revenues
Revenues
13089977
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11807867
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10028964
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35413649
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26507872
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3463655
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3021450
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10593308
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9378672
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
15271522
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
13050414
us-gaap Operating Expenses
OperatingExpenses
46006957
us-gaap Operating Expenses
OperatingExpenses
35886544
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-13009880
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6864600
us-gaap Operating Income Loss
OperatingIncomeLoss
-34867001
us-gaap Operating Income Loss
OperatingIncomeLoss
-22796567
CY2024Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
453152
CY2023Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
479380
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
1516418
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
1276502
CY2023Q3 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-5388
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-5388
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
453152
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
473992
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1516418
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1271114
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-12556728
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-6390608
us-gaap Net Income Loss
NetIncomeLoss
-33350583
us-gaap Net Income Loss
NetIncomeLoss
-21525453
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-58766
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-66485
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-139592
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
7964
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12615494
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6457093
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33490175
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21517489
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.38
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.38
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.25
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.25
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.04
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.04
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.85
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.85
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
33090063
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33090063
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25817676
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25817676
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32099181
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32099181
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
25468880
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
25468880
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
22601467
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2290244
CY2024Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
3265412
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
71888
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-9794073
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
18434938
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1985849
CY2024Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2152793
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
81222
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-152714
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-10999782
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
11502306
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
67205869
CY2024Q3 capr Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
58189
CY2024Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2051283
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
62806
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-58766
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-12556728
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
68264959
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
11786094
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2194784
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3895
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-10258
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-7768266
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
6206249
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2130395
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1618712
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
57679
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
84707
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-7366579
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
2731163
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
221081
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1717193
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-66485
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-6390608
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-1787656
us-gaap Profit Loss
ProfitLoss
-33350583
us-gaap Profit Loss
ProfitLoss
-21525453
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-5388
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1049509
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
761274
us-gaap Share Based Compensation
ShareBasedCompensation
7469488
us-gaap Share Based Compensation
ShareBasedCompensation
5530689
capr Noncash Lease Expenses
NoncashLeaseExpenses
-30941
capr Noncash Lease Expenses
NoncashLeaseExpenses
-13921
capr Increase Decrease From Grants Receivable
IncreaseDecreaseFromGrantsReceivable
-9962311
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-610711
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-461475
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
51074
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
281122
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
1868032
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-11139956
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1089977
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25199413
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14002493
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
69077305
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
72665821
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
77079337
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
84955000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
678073
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
753056
capr Payments To Acquire Leasehold Improvements
PaymentsToAcquireLeaseholdImprovements
126180
capr Payments To Acquire Leasehold Improvements
PaymentsToAcquireLeaseholdImprovements
565255
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
7197779
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
10970868
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
71481962
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2351476
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
202217
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
61574
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
71684179
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2413050
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
53682545
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-618575
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14694857
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9603242
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
68377402
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8984667
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Reclassification</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain reclassification of prior period amounts has been made to conform to the current year presentation.</p>
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-192700000
CY2024Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
85000000.0
CY2020Q4 capr Employee Retention Credit Cares Act Receivable
EmployeeRetentionCreditCaresActReceivable
738778
CY2021Q4 capr Employee Retention Credit Cares Act Receivable
EmployeeRetentionCreditCaresActReceivable
738778
CY2021 capr Employee Retention Credit Cares Act Revenue
EmployeeRetentionCreditCaresActRevenue
191199
CY2023 capr Employee Retention Credit Cares Act Revenue
EmployeeRetentionCreditCaresActRevenue
191463
CY2024Q3 capr Employee Retention Credit Cares Act Receivable
EmployeeRetentionCreditCaresActReceivable
366551
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Management uses its historical records and knowledge of its business in making these estimates. Accordingly, actual results may differ from these estimates.</p>
CY2024Q3 us-gaap Depreciation
Depreciation
361167
CY2023Q3 us-gaap Depreciation
Depreciation
276471
us-gaap Depreciation
Depreciation
1049509
us-gaap Depreciation
Depreciation
761274
CY2024Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8555208
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7766696
CY2024Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3239823
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2206055
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5315385
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5560641
capr Grant Income
GrantIncome
0
CY2023Q3 capr Grant Income
GrantIncome
0
capr Grant Income
GrantIncome
0
CY2024Q3 capr Grant Income
GrantIncome
0
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11800000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10000000.0
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35400000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26500000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12600000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6500000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33500000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21500000
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-58766
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-66485
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-139592
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
7964
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15454599
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
15454599
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8303253
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8303253
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40332392
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5041403
CY2023Q4 capr Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
5.61
capr Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
38000
capr Class Of Warrant Or Right Exercised Weighted Average Exercise Price
ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice
1.53
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5003403
CY2024Q3 capr Class Of Warrant Or Right Weighted Average Exercise Price
ClassOfWarrantOrRightWeightedAverageExercisePrice
5.64
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5003403
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5041403
capr Share Based Compensation Number Of Plans
ShareBasedCompensationNumberOfPlans
5
CY2021Q2 capr Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Annual Increase In Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfAnnualIncreaseInNumberOfSharesAuthorized
0.05
capr Minimum Limit Of Fair Market Value To Be Treated As Non Statutory Stock
MinimumLimitOfFairMarketValueToBeTreatedAsNonStatutoryStock
100000
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.16
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.93
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.56
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.88
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.09
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.19
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.11
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.21
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.039
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.045
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.035
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.045
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2051283
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1717193
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7469488
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5530689
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
16600000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y4M24D
CY2024Q3 capr Number Of Financial Institutions
NumberOfFinancialInstitutions
3
CY2024Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2024Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
85000000.0
CY2024Q3 us-gaap Short Term Lease Payments
ShortTermLeasePayments
22857
CY2023Q3 us-gaap Short Term Lease Payments
ShortTermLeasePayments
22857
us-gaap Short Term Lease Payments
ShortTermLeasePayments
787571
us-gaap Short Term Lease Payments
ShortTermLeasePayments
70071
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
226677
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
914220
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
634889
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1775786
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
127263
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1648523
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
813634
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
834889
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1648523
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y10M24D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.074
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1500000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1600000
CY2024Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
210357
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
198041
us-gaap Operating Lease Cost
OperatingLeaseCost
631072
us-gaap Operating Lease Cost
OperatingLeaseCost
583253
CY2024Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
221099
CY2023Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
199058
us-gaap Operating Lease Payments
OperatingLeasePayments
676921
us-gaap Operating Lease Payments
OperatingLeasePayments
597173
capr Severance Package To Be Paid For Period Of Base Salary
SeverancePackageToBePaidForPeriodOfBaseSalary
P6M
CY2024Q3 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
capr-20240930_cal.xml Edgar Link unprocessable
0001558370-24-015730-index-headers.html Edgar Link pending
0001558370-24-015730-index.html Edgar Link pending
0001558370-24-015730.txt Edgar Link pending
0001558370-24-015730-xbrl.zip Edgar Link pending
capr-20240930.xsd Edgar Link pending
capr-20240930x10q.htm Edgar Link pending
capr-20240930xex10d1.htm Edgar Link pending
capr-20240930xex10d6.htm Edgar Link pending
capr-20240930xex31d1.htm Edgar Link pending
capr-20240930xex31d2.htm Edgar Link pending
capr-20240930xex32d1.htm Edgar Link pending
capr-20240930xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
capr-20240930_def.xml Edgar Link unprocessable
capr-20240930_lab.xml Edgar Link unprocessable
capr-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
capr-20240930x10q_htm.xml Edgar Link completed
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending